Additional Relevant Details Roche began enrollment of its Phase 3 inhibitor study of emicizumab (formerly ACE 910) for treatment of hemophilia A and achieved first-patient-in.  Looking forward, the Company expects to initiate two more studies in 2016, one Phase 3 non-inhibitor study and a Phase 2 pediatrics inhibitor study.